SURGEPAYS INC (SURG)

US86882L2043 - Common Stock

1.65  -0.03 (-1.79%)

Fundamental Rating

4

Overall SURG gets a fundamental rating of 4 out of 10. We evaluated SURG against 22 industry peers in the Wireless Telecommunication Services industry. While SURG has a great health rating, there are worries on its profitability. SURG is valued correctly, but it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SURG was profitable.
In the past year SURG had a positive cash flow from operations.
In the past 5 years SURG reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: SURG reported negative operating cash flow in multiple years.

1.2 Ratios

SURG's Return On Assets of -2.72% is on the low side compared to the rest of the industry. SURG is outperformed by 80.95% of its industry peers.
The Return On Equity of SURG (-3.33%) is worse than 76.19% of its industry peers.
Industry RankSector Rank
ROA -2.72%
ROE -3.33%
ROIC N/A
ROA(3y)-7.37%
ROA(5y)-50.43%
ROE(3y)-107.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SURG's Gross Margin of 20.06% is on the low side compared to the rest of the industry. SURG is outperformed by 85.71% of its industry peers.
SURG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y78.16%
GM growth 5Y-10.03%

More info and screens

8

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
SURG has more shares outstanding than it did 1 year ago.
SURG has more shares outstanding than it did 5 years ago.
SURG has a better debt/assets ratio than last year.

2.2 Solvency

SURG has an Altman-Z score of 4.07. This indicates that SURG is financially healthy and has little risk of bankruptcy at the moment.
SURG has a Altman-Z score of 4.07. This is amongst the best in the industry. SURG outperforms 90.48% of its industry peers.
SURG has a debt to FCF ratio of 0.48. This is a very positive value and a sign of high solvency as it would only need 0.48 years to pay back of all of its debts.
SURG has a better Debt to FCF ratio (0.48) than 95.24% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that SURG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.10, SURG belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.48
Altman-Z 4.07
ROIC/WACCN/A
WACC7.4%

2.3 Liquidity

A Current Ratio of 7.38 indicates that SURG has no problem at all paying its short term obligations.
The Current ratio of SURG (7.38) is better than 100.00% of its industry peers.
A Quick Ratio of 6.11 indicates that SURG has no problem at all paying its short term obligations.
SURG's Quick ratio of 6.11 is amongst the best of the industry. SURG outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 7.38
Quick Ratio 6.11

More info and screens

2

3. Growth

3.1 Past

SURG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -89.29%.
Looking at the last year, SURG shows a very negative growth in Revenue. The Revenue has decreased by -21.02% in the last year.
The Revenue has been growing by 55.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-89.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-265%
Revenue 1Y (TTM)-21.02%
Revenue growth 3Y36.1%
Revenue growth 5Y55.26%
Sales Q2Q%-57.96%

3.2 Future

Based on estimates for the next years, SURG will show a very negative growth in Earnings Per Share. The EPS will decrease by -69.92% on average per year.
Based on estimates for the next years, SURG will show a very negative growth in Revenue. The Revenue will decrease by -25.28% on average per year.
EPS Next Y-157.48%
EPS Next 2Y-69.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-48.69%
Revenue Next 2Y-25.28%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 18.33, which indicates a rather expensive current valuation of SURG.
Based on the Price/Earnings ratio, SURG is valued a bit cheaper than 61.90% of the companies in the same industry.
SURG is valuated rather cheaply when we compare the Price/Earnings ratio to 30.71, which is the current average of the S&P500 Index.
SURG is valuated correctly with a Price/Forward Earnings ratio of 13.12.
SURG's Price/Forward Earnings ratio is in line with the industry average.
SURG's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.09.
Industry RankSector Rank
PE 18.33
Fwd PE 13.12

4.2 Price Multiples

SURG's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SURG is cheaper than 95.24% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.26
EV/EBITDA N/A

4.3 Compensation for Growth

SURG's earnings are expected to decrease with -69.92% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.92%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SURG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (9/16/2024, 8:00:00 PM)

1.65

-0.03 (-1.79%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.57M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 18.33
Fwd PE 13.12
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.72%
ROE -3.33%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 20.06%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.38
Quick Ratio 6.11
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-89.29%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-157.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.02%
Revenue growth 3Y36.1%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y